Second Line Therapy in Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the therapeutic activity of capecitabine alone or in
combination with mitomycin C as second-line therapy in patients with advanced/metastatic
biliary adenocarcinoma in progression after gemcitabine and platinum compounds